Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.65 |
| ▸ | AURKA | O14965 | 11/20 | 0.61 |
| ▸ | IGF1R | P08069 | 2/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.56 |
| ▸ | JAK3 | P52333 | 2/20 | 0.56 |
| ▸ | EGFR | P00533 | 3/20 | 0.55 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30353197 | 0.88 | EGFR (0.57) | PIK3C3AURKAAURKBEGFRRIPK1 | |
| SCHEMBL30353149 | 0.87 | AURKA (0.60) | PIK3C3AURKAAURKBEGFRRIPK1 | |
| SCHEMBL12430891 | 0.87 | EGFR (0.70) | PIK3C3AURKAAURKBJAK3EGFR | |
| SCHEMBL18154662 | 0.84 | EGFR (0.53) | PIK3C3AURKAAURKBEGFRTBK1 | |
| SCHEMBL12430920 | 0.82 | PIK3C3 (0.59) | PIK3C3AURKAIGF1RAURKBJAK3 | |
| SCHEMBL12430918 | 0.79 | PIK3C3 (0.55) | PIK3C3AURKAIGF1RAURKBJAK3 | |
| SCHEMBL12430837 | 0.78 | AURKA (0.61) | PIK3C3AURKAIGF1RAURKBJAK3 | |
| SCHEMBL16065409 | 0.77 | PIK3C3 (0.57) | PIK3C3AURKAIGF1RAURKBJAK3 | |
| SCHEMBL17175910 | 0.77 | PIK3C3 (0.57) | PIK3C3AURKAIGF1RAURKBJAK3 | |
| SCHEMBL15705096 | 0.77 | PIK3C3 (0.55) | PIK3C3AURKAIGF1RAURKBJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2023-03-28 | — | — | US | disclosed |
| EP-3283482-A1 | PLK4 INHIBITORS | Ludwig Institute for Cancer Research Ltd (CH) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016166604-A1 | PLK4 INHIBITORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | PLK4, PLK2, PLK3 | PIK3C3 1540/4885AURKA 71/4885IGF1R 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.